In ovarian cancer, it was found that the frequency of the FBXW7 gene mutation is approximately 2.5 ~ 8.3% [19, 20] and the downregulation of FBW7 expression can be attributed to the TP53 gene mutation, particularly, in the serous carcinoma samples with the TP53 mutation frequency of ~ 95% [21–23]. This evidence concerns the gene TP53 and serous adenocarcinoma.